EUVIMEDEUVIMED entdecken
Crossref

Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care

Integrative Biomedical Research · 2026

DOI: 10.25163/biomedical.10110910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Integrative Biomedical Research, 2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity has become one of the defining chronic diseases of this century, and the arrival of glucagon-like peptide-1 (GLP-1) receptor agonists and multi-receptor co-agonists has, arguably, changed what clinicians can honestly promise their patients. Still, it is worth asking whether the enthusiasm surrounding these agents has outpaced our understanding of who benefits, who is left behind, and what happens once the injections stop. This review set out to synthesize the current evidence on the efficacy, tolerability, equity, and durability of incretin-based obesity pharmacotherapy across adult and pediatric populations. We conducted a structured narrative synthesis of nineteen peer-reviewed sources published largely between 2024 and 2026, retrieved through a search strategy combining controlled vocabulary and free-text terms related to obesity, GLP-1 receptor agonists, dual and triple incretin co-agonists, treatment persistence, and body composition. Screening, data extraction, and thematic organization followed a reproducible, pre-specified protocol suitable for replication. Selective GLP-1 receptor agonists produce mean weight reductions near 15%, dual GIP/GLP-1 agonism extends this to 20.9-22.5%, and triple agonism reaches up to 24.2% at 48 weeks. These gains, however, come bundled with real costs: gastrointestinal intolerance drives 46-65% of patients to discontinue therapy within a year, lean mass accounts for roughly a quarter to two-fifths of total weight lost, and persistence rates vary almost sevenfold between reimbursed and out-of-pocket healthcare systems. Incretin-based pharmacotherapy has undeniably narrowed the gap between medical and surgical obesity treatment, but its long-term value will hinge on solving three stubborn problems-tolerability, affordability, and the preservation of lean tissue-rather than on chasing further increments in weight-loss percentages alone.

Zitieren

APA

(2026). Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care. Integrative Biomedical Research. https://doi.org/10.25163/biomedical.10110910

Vancouver

Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care. Integrative Biomedical Research. 2026. doi:10.25163/biomedical.10110910

BibTeX
@article{euvimed2026,
  title = {Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care},
  journal = {Integrative Biomedical Research},
  year = {2026},
  doi = {10.25163/biomedical.10110910}
}
Kostenlos starten →